Proteome Sciences PLC - drug development services provider - Amends £1 million loan with Vulpes Investment Management Private Ltd, which was signed in the summer of 2018. Accrued interest now repayable on June 30, 2023, extended from May 1, 2022. Notes £700,000 is currently drawn on facility.

Martin Diggle, non-executive director of Proteome Sciences, is a director and partner of VIM. VIM manages the Vulpes Life Sciences Fund, which owns a 22.3% stake in Proteome Sciences.

Current stock price: 3.62 pence

12-month change: down 28%

Copyright 2022 Alliance News Limited. All Rights Reserved.